To confirm the potential of the anti-B220 MSN-DN to impair AML LSC activity, B220+ AML LSCs were treated with either untagged MSNs, anti-B220 MSNs, free DN, anti-HuCD9 MSN-DN or anti-B220 MSN-DN for 24 hours. Here, PTPRC is linked to acute myeloid leukemia.